D Orazio & Associates Inc. Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

D Orazio & Associates Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,332 shares of the biopharmaceutical company’s stock after purchasing an additional 1,250 shares during the period. D Orazio & Associates Inc.’s holdings in Gilead Sciences were worth $597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Redwood Financial Network Corp grew its position in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 98 shares during the last quarter. Nicolet Advisory Services LLC boosted its stake in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the period. Peak Financial Advisors LLC grew its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co increased its stake in Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 100 shares during the period. Finally, CFO4Life Group LLC lifted its holdings in Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 112 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $109.98 on Friday. The company has a market cap of $136.81 billion, a price-to-earnings ratio of 297.24, a PEG ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock’s fifty day moving average price is $105.67 and its 200 day moving average price is $102.26. Gilead Sciences, Inc. has a 1 year low of $62.69 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The company’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period last year, the business posted ($1.32) earnings per share. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s payout ratio is currently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares of the company’s stock, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the sale, the chief executive officer now owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,000 shares of company stock valued at $4,630,310 over the last 90 days. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Bank of America upped their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.